,36–38 In 2008, the first successful clinical application of RPE65 gene augmentation therapy in patients with Leber congenital amaurosis or early-onset RP demonstrated both the safety and efficacy of this approach, leading to the first FDA-approved gene therapy for retinal disease.20 Here, RPE65 is linked to Abnormal retinal morphology.